CNDT vs. GDRX, UPWK, XMTR, OLO, PHR, LZ, NVEE, VVX, TASK, and UPBD
Should you be buying Conduent stock or one of its competitors? The main competitors of Conduent include GoodRx (GDRX), Upwork (UPWK), Xometry (XMTR), OLO (OLO), Phreesia (PHR), LegalZoom.com (LZ), NV5 Global (NVEE), V2X (VVX), TaskUs (TASK), and Upbound Group (UPBD). These companies are all part of the "business services" industry.
Conduent vs. Its Competitors
Conduent (NASDAQ:CNDT) and GoodRx (NASDAQ:GDRX) are both small-cap business services companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.
Conduent has higher revenue and earnings than GoodRx. Conduent is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.
In the previous week, Conduent had 1 more articles in the media than GoodRx. MarketBeat recorded 1 mentions for Conduent and 0 mentions for GoodRx. Conduent's average media sentiment score of 0.78 beat GoodRx's score of 0.00 indicating that Conduent is being referred to more favorably in the media.
GoodRx has a consensus price target of $6.55, indicating a potential upside of 37.80%. Given GoodRx's stronger consensus rating and higher possible upside, analysts plainly believe GoodRx is more favorable than Conduent.
Conduent has a net margin of 8.66% compared to GoodRx's net margin of 3.57%. GoodRx's return on equity of 7.85% beat Conduent's return on equity.
77.3% of Conduent shares are held by institutional investors. Comparatively, 63.8% of GoodRx shares are held by institutional investors. 3.0% of Conduent shares are held by company insiders. Comparatively, 4.2% of GoodRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Conduent has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, GoodRx has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.
Summary
GoodRx beats Conduent on 9 of the 17 factors compared between the two stocks.
Get Conduent News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNDT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CNDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Conduent Competitors List
Related Companies and Tools
This page (NASDAQ:CNDT) was last updated on 7/21/2025 by MarketBeat.com Staff
Free CNDT Stock Alerts